Bornfeldt Glucose and Atherosclerosis 191 mortality resulting from the use of this SGLT2 inhibitor may not be because of reduced atherosclerotic events, but rather because of altered hemodynamics, causing an impressive protection against heart failure, 8, 9 although it cannot be ruled out that empagliflozin acts in part by stabilizing atherosclerotic lesions. SGLT2 inhibitors act by inhibiting glucose reabsorption in the kidney with an increased glucose excretion and blood glucose–lowering effect as a result. We are now awaiting confirmation of these findings by other SGLT2 inhibitors.